Last reviewed · How we verify
NCT07032246: PROCLAIM
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NA trial testing quantitative brain MRI (icobrain mr) in Multiple Sclerosis in 750 participants. Enrolling by invitation.
31 August 2028
Quick facts
| Lead sponsor | icometrix |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | diagnostic |
| Enrollment | 750 |
| Start date | 9 October 2025 |
| Primary completion | 31 August 2028 |
| Estimated completion | 30 November 2028 |
| Sites | 6 locations across Italy, Germany, Czechia |
Drugs / interventions tested
- quantitative brain MRI (icobrain mr)
- Standard of Care (SOC) — full drug profile →
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Radiologically Isolated Syndrome — all drugs for Radiologically Isolated Syndrome →
- Clinically Isolated Syndrome — all drugs for Clinically Isolated Syndrome →
Sponsor
icometrix
Who can join
18 and older, any sex, with Multiple Sclerosis or Radiologically Isolated Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of the PROCLAIM study is to assess the effectiveness of quantitative brain MRI, as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering disease, and the downstream effects on clinical decision making and patient outcomes in a real-world setting. The study will compare an intervention arm implementing quantitative brain MRI (using the CE-marked medical device software icobrain mr) as part of Standard of Care, and a control arm implementing Standard of Care without quantitative brain MRI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07032246
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other icometrix trials
Trials by the same sponsor.
- NCT05671055 — CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07032246 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by icometrix
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07032246.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing